Medicine and health products import and export chamber of commerce(Hereinafter referred as the Medical Insurance Chamber of Commerce) in China held the seven-time secondary Medical Insurance Chamber of Commerce council and seven session of the standing council at a time in Fuzhou province during March 21 to 24. Almost 100 medical representatives of more than 80 Chamber of Commerce member companies all over the country attended the meeting. The meeting focused on the development opportunities and prospects of medical health industry under the new situation, and went into depth on how to make council work and industry work benefit each other that promoting the industry into a new level.

  As the council member of the Medical Insurance Chamber , Arshine ,the biological technology company in Hunan province, was invited to participate in this meeting. The chairman of Arshine Chen Aiping accepted the interview by the Chamber of Commerce of Medical Insurance during the conference. Mrs Chen frankly introduced the main reasons of the rapid development of Arshine in recent years to Yu Meng of Medical Insurance Chamber of Commerce, and shared the strategic layout and developing emphasis of Arshine in the next three years.

     In recent years, Arshine has a rapid business development which depends on correct strategic position and operation strategy, the advanced model of management and the hard work of the team. In 2017, exportation of Arshine exceeded one billion dollars and entered the top 100 list of Chinese pharmaceutical export enterprises, ranking the eight-ninth place. In June 2017, Arshine gained two awards of “The excellent supplier and partner in the international market in 2017” and “The most powerful enterprise in 2017” by Medical Insurance Chamber of Commerce.

     Arshine, who has entered the governing board of the Medical Insurance Chamber of Commerce, takes the initiative to work on the corporate mission of enhancing the international status of Chinese medicine, and promotes the development of the industry with his own development experience. Mrs.Chen represented the pharmaceutical foreign trade company in the closed session of the board of directors. In particular, she pointed out that the primary task of the overseas market of the pharmaceutical API industry in the next few years should be better manage the market, build channels, and maintain the ecological environment of the market to avoid the API blind competing with others in low prices, selling Chinese API in a low price, destroying the market ecology both at home and abroad, which leads to huge damage to API production and trading companies in China.Mrs. Chen pointed out that excellent foreign trade companies should work hard to cultivate market channels, work as craftsmen of overseas channel construction, and help China's API companies to have a more stable, deeper, and more sustainable overseas distribution.